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Abstract
Objectives. We aimed to estimate what proportion of people with SLE attending UK rheumatology clinics would
be categorized as being at high risk from coronavirus disease 2019 (COVID-19) and therefore asked to shield, and
explore what implications this has for rheumatology clinical practice.
Methods. We used data from the British Society for Rheumatology multicentre audit of SLE, which included a
large, representative cross-sectional sample of patients attending UK Rheumatology clinics with SLE. We calculated
who would receive shielding advice using the British Society for Rheumatology’s risk stratification guidance and
accompanying scoring grid, and assessed whether ethnicity and history of nephritis were over-represented in the
shielding group.
Results. The audit included 1003 patients from 51 centres across all 4 nations of the UK. Overall 344 (34.3%)
patients had a shielding score 3 and would have been advised to shield. People with previous or current LN
were 2.6 (1.9–3.4) times more likely to be in the shielding group than people with no previous LN (P<0.001).
Ethnicity was not evenly distributed between the groups (chi-squared P< 0.001). Compared with White people,
people of Black ethnicity were 1.9 (1.3–2.8) and Asian 1.9 (1.3–2.7) times more likely to be in the shielding group.
Increased risk persisted after controlling for LN.
Conclusion. Our study demonstrates the large number of people with SLE who are likely to be shielding.
Implications for clinical practice include considering communication across language and cultural differences, and
ways to conduct renal assessment including urinalysis, during telephone and video consultations for patients who
are shielding.
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shielding.
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Coronavirus disease 2019 (COVID-19) presents a
unique challenge in that it poses a threat to the entire
population. However, there is a subset of the population
who have been defined by the UK’s Chief Medical
Officers to be ‘extremely vulnerable’ to severe illness
from COVID-19. The defined criteria for identifying the
‘extremely vulnerable’ group includes ‘People on im-
munosuppression therapies sufficient to significantly
increase risk of infection’ [1], which is likely to apply to
many people with autoimmune rheumatic diseases. In
order to protect their health, these people have been
advised to adopt extreme social distancing measures
termed ‘Shielding’.
Patients in this shielding category were identified in
England using data accessed and searched by National
Health Service (NHS) Digital, and patients were con-
tacted by letter through this national process. General
practitioners and hospital clinicians in each NHS Trust
were asked to identify and contact additional patients
who would meet clinical criteria for shielding but who
were not identified by NHS Digital. The UK devolved
nations (Scotland, Wales, Northern Ireland) used similar
country-specific methodology [2–4].
In order to guide identification of these ‘extremely vul-
nerable’ patients by clinicians, the British Society for
Rheumatology (BSR) established a working group to de-
fine immunosuppression therapies sufficient to signifi-
cantly increase risk of infection in the context of patients
treated by rheumatologists [5]. The group produced a
risk stratification guide and an accompanying scoring
grid, where a score of 3 or more meant that people
should be advised to ‘shield’ themselves [6]. Both
resources reliably identified those needing to shield, al-
though the scoring grid has now been removed from the
BSR website, because of some minor discrepancies be-
tween this and the stratification guide [7].
Rheumatology services have been made aware of the
concern caused by shielding and inconsistent informa-
tion from different health providers, not least through the
greatly increased number of calls to rheumatology ad-
vice lines. LUPUS UK (a patient charity) describe receiv-
ing numerous reports from people with lupus who are
shielding and experiencing hardship and difficulty
accessing essential support [P. Howard, CEO Lupus
UK, 2020 (personal communication)]. The solitary con-
finement experienced by those advised to shield is a
heavy burden. Patients who are shielding are told they
should not leave their home even for shopping, and ei-
ther the whole household shields, or they should isolate
themselves from other people in their home, keeping 2
m away at all times and eating alone in their room [8].
The requirement to shield is likely to be disproportion-
ately high among people with rare autoimmune rheumat-
ic diseases, such as SLE, because of frequent long-term
CS and immunosuppressant use in these conditions,
and high levels of comorbidity. However, what is not
known is the burden of shielding amongst different
groups of people with autoimmune rheumatic diseases.
We used data from the BSR multicentre audit of SLE,
which included a large and representative cross-
sectional sample of patients attending UK Rheumatology
clinics with SLE, to calculate their shielding scores, and
to explore what implications this has for rheumatology
clinical practice now and in the future.
Methods
Full methods for the audit are described in ‘BSR
Guideline on the Management of Adults with SLE 2018:
Baseline MultiCentre Audit in the UK’ (submitted with
this paper). In brief, 51 rheumatology units in the 4
nations of the UK retrospectively audited care at the
preceding clinic visit of prevalent SLE cases attending
during a 4-week period in February–June 2018. Data
including patient demographics, medications (including
CS dose) and comorbidities were collected using web-
based survey software. For this analysis, ethnic groups
containing fewer than 50 people were categorized as
other, resulting in ethnic group categories of White,
Asian or Asian British, Black or Black British, Other eth-
nic groups, or not stated.
We applied the BSR risk stratification (scoring) grid to
find out who would have qualified for shielding advice
according to the COVID-19 guidance. This allocated
points for CS dose (0 points if no steroids or daily dose
<5 mg daily, 2 points if daily dose 5 mg and <20 mg,
and 3 points if daily dose 20 mg daily), number of
immunosuppressants (1 point if one DMARD or biologic
and 2 points if two or more DMARDs or biologics;
excluding HCQ and SSZ), CYC (3 points if given in the
past 6 months) and 1 point if any one or more of: age
>70 years, diabetes mellitus, pre-existing lung disease,
renal impairment, history of ischaemic heart disease or
hypertension. Scores for each category are summed,
and a person with a score 3 should be advised to
shield.
We applied all of the risk factors in the BSR’s ‘Risk
stratification of patients with autoimmune rheumatic dis-
eases’ [6]. However, the audit data recorded CS dose at
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. More than a third of patients with SLE may be shielding during the coronavirus disease 2019 (COVID-19) pandemic.
. Patients from Black and minority ethnic (BAME) backgrounds are over-represented in the shielding group.
. Half of patients with previous LN are shielding and may miss urinalysis due to telephone consultations.
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a single time-point at the end of the preceding clinic
visit, whereas the risk stratification grid allocated points
for dose over the preceding 4 weeks. We assumed that
patients were on the steroid dose we recorded for at
least 4 weeks, because most steroid courses for SLE
last at least this long. We did not have data on the least
frequent of the listed comorbidities, namely pre-existing
lung disease, so could not include this stratification. We
conducted sensitivity analyses to assess what impact
our assumption about length of CS courses, and the
omission of pre-existing lung disease, might have had
on our results.
We assigned each patient a shielding score and a
shielding status (yes/no). We used ethnicity reported in
the audit (taken from the self-reported ethnicity collected
at inpatient and outpatient attendances to hospital and
recorded on hospital computer systems). We also
included presence or absence of previous LN. We com-
pared the distribution of shielding status with the distri-
bution of ethnicity, and with whether a patient had
previously had LN using chi-squared testing and logistic
regression. We included a multivariable regression ana-
lysis to estimate the adjusted odds ratio for the effect of
ethnicity on shielding status, while controlling for LN.
This manuscript is based on clinical audit data and so
ethical approval and informed consent was not required.
Participating units registered the audit with their local
audit departments. Data collection was hosted by the
Audit department at the Dudley Group NHS Foundation
Trust.
Results
The audit included 1003 patients. Patients were aged a
median age of 48 (interquartile range 36–58) years, and
935 (93%) were female. Overall, 586 (58.4%) were
White, 157 (15.7%) Asian or Asian British, and 147
(14.7%) Black or Black British; Other ethnic groups each
contributed <5%. A total of 497 (48.7%) patients were
on prednisolone. This included 95 (9.5%) on a dose
<5 mg daily, 347 (34.6%) on a dose 5 mg and <20 mg
daily, and 55 (5.5%) on a dose 20 mg daily.
Overall 344 (34.3%) patients had a shielding score 3
and would have been advised to shield. The distribution
of scores is shown in Table 1.
Ethnicity was not evenly distributed between the
shielding and not shielding groups (chi-squared
P<0.001), and people of Black, Asian and minority eth-
nic (BAME) ethnicities were more likely than those of
White ethnicity to be in the shielding group. Compared
with White people, people of Black ethnicity were 1.9
(1.3–2.8) and Asian 1.9 (1.3–2.7) times more likely to be
in the shielding group (Table 2). Mixed ethnicity and
Other ethnic groups did not show statistically significant
differences from White people, but the numbers were
small. People with previous or current LN were 2.6 (95%
CI 1.9, 3.4) times more likely to be in the shielding group
than people with no previous LN. Overall, 243 (24.2%)
patients in the audit had had LN, and of these 124
(51.0%) were in the shielding group compared with 220
(28.9%) of 760 patients without previous LN (P<0.001).
Multivariable regression analysis was performed to es-
timate the adjusted odds ratio for the effect of ethnicity
on shielding status, while controlling for LN. This con-
firmed increased odds of being asked to shield in the
Asian or Asian British, and Black or Black British groups,
independent of their history of LN. Asian or Asian British
people were 1.7 (95% CI 1.2, 2.5) times more likely than
White people to be in the shielding group, and Black or
Black British people were 1.7 (95% CI 1.1, 2.4) times
more likely. The odds ratio for Other ethnic groups was
not significant.
Discussion
In a large representative sample of people living with
SLE in the UK we found that just over a third would be
eligible for shielding. This illustrates the large burden of
shielding and of perceived risk being carried at this time
by people with SLE in the UK, and around the world.
Our study included a large and representative sample
of people with lupus living in the UK. It included people
from all four nations of the UK, attending both large and
small hospitals. Demographics were similar to other
published UK cohorts of people with SLE [9–12]. Our
paper contains good quality data, collected by doctors
from medical notes from the clinic visit prior to the audit
time frame to avoid bias. There were no missing data
because the web-based survey software did not allow
submission until all fields were completed. Data were
collected in 2018, and it is likely that the clinical charac-
teristics and management of cohorts of patients with
SLE are similar today.
There are of course some limitations. We did not have
data on whether each patient had been on their current
dose of steroids for at least 4 weeks, and we assumed
that they had. However, we think this had a negligible
effect on the shielding status. We tested whether in peo-
ple on doses of prednisolone >20 mg daily we were
over-estimating the number who would be eligible for
shielding by giving them 3 points. We thought it almost
certain that someone on 20 mg of prednisolone would
TABLE 1 Shielding scores in the 1003 people included in the
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be on a dose of 5 mg for at least 4 weeks and so
would be awarded at least 2 points. If all the people on
prednisolone >20 mg had received only 2 points for
steroid dose, then only 13 people would have moved
from the shielding group into the non-shielding group
(because all except 13 people on high-dose steroids
qualified for shielding for other reasons in addition). We
also did not have data to estimate the number of people
who had pre-existing lung disease, and it is possible
that a small number who did not already receive a point
for being aged >70 years and other comorbidities could
have gained an extra point. Potentially, this means that
up to 75 (7.5%) people who had a total shielding score
of 2 and were <70 years with no comorbidities should
be in the shielding group, but we think in reality that this
group is likely to be very small, as pre-existing lung dis-
ease is not common in SLE.
This is the first report we are aware of describing the
burden of shielding on patients with SLE or other rare
autoimmune rheumatic diseases in the UK.
This paper describes a high requirement for shielding
amongst people with SLE during the COVID-19 pan-
demic. It highlights that a high proportion of people liv-
ing with SLE have been identified as being at high risk
of severe disease if they are infected with COVID-19. It
also alerts us to a challenge for how we reduce harm by
maintaining healthcare services for this group. We found
that shielding was disproportionately indicated in people
with previous LN compared with those who have never
had LN. An increased chance of shielding was also seen
among people with SLE of BAME background com-
pared with people of White ethnicity, and this effect
persisted despite controlling for history of LN. Most
rheumatology services in the UK have switched to offer-
ing telephone or video consultations, rather than face-
to-face follow-up, following the National Institute for
Health and Care Excellence (NICE) rapid guidance [13].
The shielding groups have been advised to stay at
home for at least 12 weeks, and will require telephone
consultations for this 3-month period, and possibly lon-
ger. For people from BAME backgrounds we need to
address barriers to accessing healthcare that may be
exacerbated by telephone consultations [14–16]. For
everyone with SLE we need to complete renal assess-
ment including urinalysis, renal function by blood tests
and blood pressure check alongside telephone consul-
tations. Although the NICE rapid guidance advises that
services plan remote blood monitoring for DMARDs
there is no mention of remote urine or blood pressure
monitoring. This is essential to detect LN, which is often
asymptomatic, is potentially organ or life-threatening,
and is more common in people with previous nephritis.
Whilst there is an evolving picture around the use of
CS and COVID-19, the multi-speciality Clinical guide for
the management of patients with musculoskeletal and
rheumatic conditions on CS during the coronavirus pan-
demic describes the theoretical risks of more severe
COVID-19 infection amongst this group [17]. It is notable
that nearly half of the people in the audit were on pred-
nisolone, and over a third were on a dose of 5 mg daily,
which is currently thought to be sufficient to increase
the risk of severe infection with COVID-19. There is clear
advice not to stop CS suddenly, due to the risk of
Addisonian crisis and lupus flare, but to taper the dose
if possible. An urgent research priority should be to in-
vestigate the safety of steroid usage in lupus and other
rare autoimmune rheumatic diseases, and how to main-
tain disease remission with a lower steroid burden.
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